Aspirin in a Diabetic Retinopathy Setting: insights from NO BLIND Study

Background and Aims Diabetic retinopathy (DR) is the most common microvascular complication of diabetes. Diabetic macroangiopathies, particularly cardiovascular (CV) diseases, seems closely related to diabetes microvascular complications. Aspirin represents the most prescribed compound in CV prevention. Aspirin impact on DR is still object of debate. As aspirin is already recommended among diabetics at high CV risk, aim of this study was to assess a potential relationship between DR and aspirin therapy, in a type 2 diabetes cohort of patients screened through telemedicine. Methods and Results NO Blind is a cross-sectional, multicenter, observational study, which involved nine Italian outpatient clinics. Primary endpoint was the assessment of relationship between aspirin treatment and DR. 2 068 patients were enrolled in the study, subsequently split into two subpopulations according to either presence or absence of DR. Overall, 995 subjects were under aspirin therapy. After adjusting for most common potential confounders, age and gender, aspirin was significantly associated with DR (OR: 1.72, 95%CI: 1.58–2.89, p=0.002) and proliferative DR (PDR) (OR: 1.89, 95%CI: 1.24-2.84, p=0.003). Association comes lost further adjusting for MACEs (OR: 1.28, 95%CI: 0.85–1.42, p=0.157) (Model 4) and eGFR (OR: 0.93; 95%CI: 0.71-1.22; p=0.591) (Model 5). Conclusion In this multicenter cross-sectional study including a large sample of outpatients with T2DM, we showed that aspirin was not associated with DR after adjustment for several cardio-metabolic confounders. However, as partially confirmed by our findings, and related to the well-known pro-hemorrhagic effect of aspirin, its use should be individually tailored, even by telemedicine tools